1. Brown LJ, Löe H. Prevalence, extent, severity and progression of periodontal disease. Periodontol 2000. (1993) 2:57–71. doi: 10.1111/j.1600-0757.1993.tb00220.x
2. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. (2005) 366:1809–20. doi: 10.1016/S0140-6736(05)67728-8
3. Ramseier CA, Rasperini G, Batia S, Giannobile WV. Advanced reconstructive technologies for periodontal tissue repair. Periodontol 2000. (2012) 59:185–202. doi: 10.1111/j.1600-0757.2011.00432.x
4. Gestrelius S, Lyngstadaas SP, Hammarström L. Emdogain–periodontal regeneration based on biomimicry. Clin Oral Investig. (2000) 4:120–25. doi: 10.1007/s007840050127
5. Hammarström L. Enamel matrix, cementum development and regeneration. J Clin Periodontol. (1997) 24:658–68. doi: 10.1111/j.1600-051X.1997.tb00247.x
6. Sculean A, Kiss A, Miliauskaite A, Schwarz F, Arweiler NB, Hannig M. Ten- year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. (2008) 35:817–24. doi: 10.1111/j.1600-051X.2008.01295.x
7. Chen E, Piddington R, Decker S, Park J, Yuan ZA, Abrams WR, et al. Regulation of amelogenin gene expression during tooth development. Dev Dyn. (1994) 199:189–98. doi: 10.1002/aja.1001990304
8. Yamakoshi Y. Porcine amelogenin: alternative splicing, proteolytic processing, protein-protein interactions, and possible functions. J Oral Biosci. (2011) 53:275–83. doi: 10.1016/S1349-0079(11)80011-3
9. Du C, Falini G, Fermani S, Abbott C, Moradian-Oldak J. Supramolecular assembly of amelogenin nanospheres into birefringent microribbons. Science. (2005) 307:1450–4. doi: 10.1126/science.1105675
10. Hatakeyama J, Sreenath T, Hatakeyama Y, Thyagarajan T, Shum L, Gibson CW, et al. The receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenic pathway is elevated in amelogenin-null mice. J Biol Chem. (2003) 278:35743–8. doi: 10.1074/jbc.M306284200
11. Daley WP, Peters SB, Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci. (2008) 121:255–64. doi: 10.1242/jcs.006064
12. Jepsen S, Heinz B, Jepsen K, Arjomand M, Hoffmann T, Richter S, et al. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal Class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes. J Periodontol. (2004) 75:1150–60. doi: 10.1902/jop.2004.75.8.1150
13. Almqvist S, Werthén M, Lyngstadaas SP, Gretzer C, Thomsen P. Amelogenins modulate cytokine expression in LPS-challenged cultured human macrophages. Cytokine. (2012) 58:274–9. doi: 10.1016/j.cyto.2012.02.001
14. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med. (1993) 178:2243–7. doi: 10.1084/jem.178.6.2243
15. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. (2001) 19:93–129. doi: 10.1146/annurev.immunol.19.1.93
16. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. (1993) 178:2249–54. doi: 10.1084/jem.178.6.2249
17. Schneeberger EE, DeFerrari M, Skoskiewicz MJ, Russell PS, Colvin RB. Induction of MHC-determined antigens in the lung by interferon-gamma. Lab Invest. (1986) 55:138–44.
18. Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol. (2012) 12:813–20. doi: 10.1038/nri3339
19. Fleischer J, Soeth E, Reiling N, Grage-Griebenow E, Flad HD, Ernst M. Differential expression and function of CD80 (B7-1) and CD86 (B7- 2) on human peripheral blood monocytes. Immunology. (1996) 89:592–8. doi: 10.1046/j.1365-2567.1996.d01-785.x
20. Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J. Air-1, a newly found locus on mouse chromosome 16 encoding a trans- acting activator factor for MHC class II gene expression. J Exp Med. (1986) 164:369–74. doi: 10.1084/jem.164.1.369
21. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or gare lymphocyte syndrome). Cell. (1993) 75:135–46. doi: 10.1016/S0092-8674(05)80090-X
22. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimie V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. (2000) 14:1156−66. doi: 10.1101/gad.14.9.1156
23. Reith W, LeibundGut-Landmann S, Waidburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol. (2005) 5:793–806. doi: 10.1038/nri1708
24. Glomsda BA, Blaheta RA, Hailer NP. Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord. (2003) 41:610–9. doi: 10.1038/sj.sc.3101512
25. Kwiek B, Peng WM, Allam JP, Langner A, Bieber T, Novak N. Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol. (2008) 122:126–32. doi: 10.1016/j.jaci.2008.05.005
26. Panjwani N, Akbari O, Garcia S, Brazil M, Stockinger B. The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. J Immunol. (1999) 163:1936–42.
27. Chávez-Galán L, Olleros ML, Vesin D, Garcia I. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages. Front Immunol. (2015) 6:263. doi: 10.3389/fimmu.2015.00263
28. Spiller KL, Anfang RR, Spiller KJ, Ng J, Nakazawa KR, Daulton JW, et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds. Biomaterials. (2014) 35:4477–88. doi: 10.1016/j.biomaterials.2014.02.012
29. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. (2008) 111:5054–63. doi: 10.1182/blood-2007-12-130609
30. Carleton MM, Sefton MV. Injectable and degradable methacrylic acid hydrogel alters macrophage response in skeletal muscle. Biomaterials. (2019) 223:119477. doi: 10.1016/j.biomaterials.2019.119477
31. Sanui T, Fukuda T, Yamamichi K, Toyoda K, Tanaka U, Yotsumoto K, et al. Microarray analysis of the effects of amelogenin on U937 monocytic cells. Am J Mol Biol. (2017) 7:107–22. doi: 10.4236/ajmb.2017.72009
32. Fukuda T, Sanui T, Toyoda K, Tanaka U, Taketomi T, Uchiumi T, et al. Identification of novel amelogenin-binding proteins by proteomics analysis. PLoS ONE. (2013) 8:e78129. doi: 10.1371/journal.pone.0078129
33. Jenuwein T, Allis CD. Translating the histone code. Science. (2001) 293:1074–80. doi: 10.1126/science.1063127
34. Beresford GW, Boss JM. CIITA coordinates multiple histone acetylation modifications at the HLA-DR promoter. Nat immunol. (2001) 2:652–7. doi: 10.1038/89810
35. Snowden AW, Gregory PD, Case CC, Pabo CO. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol. (2002) 12:2159–66. doi: 10.1016/S0960-9822(02)01391-X
36. Boyd NH, Morgan JE, Greer SF. Polycomb recruitment at the Class II transactivator gene. Mol Immunol. (2015) 67(2 Pt B):482–91. doi: 10.1016/j.molimm.2015.08.003
37. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. (1993) 259:1739–42. doi: 10.1126/science.8456300
38. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. (2003) 3:23–35. doi: 10.1038/nri978
39. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. (2008) 8:958–69. doi: 10.1038/nri2448
40. Mantovani A, Sica A, Sozzani S, Allavena P, ecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. (2004) 25:677–86. doi: 10.1016/j.it.2004.09.015
41. Montaner LJ, Silva RP, Sun J, Sutterwala S, Hollinshead M, Vaux D, et al. Type 1 and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as opposed to IFN-gamma or IL-10. J Immunol. (1999) 162:4606–13.
42. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. (1999) 17:701–38. doi: 10.1146/annurev.immunol.17.1.701
43. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. (2004) 40:1660–7. doi: 10.1016/S0959-8049(04)00285-0
44. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. (2004) 76:509–13. doi: 10.1189/jlb.0504272
45. Yamamichi K, Fukuda T, Sanui T, Toyoda K, Tanaka U, Nakao Y, et al. Amelogenin induces M2 macrophage polarisation via PGE2/cAMP signalling pathway. Arch Oral Biol. (2017) 83:241–51. doi: 10.1016/j.archoralbio.2017.08.005
46. Hoang AM, Klebe RJ, Steffensen B, Ryu OH, Simmer JP, Cochran DL. Amelogenin is a cell adhesion protein. J Dent Res. (2002) 81:497–500. doi: 10.1177/154405910208100713
47. Matsuzawa M, Sheu TJ, Lee YJ, Chen M, Li TF, Huang CT, et al. Putative signaling action of amelogenin utilizes the Wnt/beta-catenin pathway. J Periodontal Res. (2009) 44:289–296. doi: 10.1111/j.1600-0765.2008.01091.x
48. Swanson EC, Fong HK, Foster BL, Paine ML, Gibson CW, Snead ML, et al. Amelogenins regulate expression of genes associated with cementoblasts in vitro. Eur J Oral Sci. (2006) 1:239–43. doi: 10.1111/j.1600-0722.2006.00321.x
49. Iacob S, Veis A. Identification of the functional activity of the [A-4] amelogenin gene splice product in newborn mouse ameloblasts. Bone. (2008) 42:1072–9. doi: 10.1016/j.bone.2008.01.023
50. Bartlett JD, Ganss B, Goldberg M, Moradian-Oldak J, Paine ML, Snead ML, et al. Protein-protein interactions of the developing enamel matrix. Curr Top Dev Biol. (2006) 74:57–115. doi: 10.1016/S0070-2153(06)74003-0
51. Tompkins K, George A, Veis A. Characterization of a mouse amelogenin [A-4]/M59 cell surface receptor. Bone. (2006) 38:172–80. doi: 10.1016/j.bone.2005.08.013
52. Wang H, Tannukit S, Zhu D, Snead ML, Paine ML. Enamel matrix protein interactions. J Bone Miner Res. (2005) 20:1032–40. doi: 10.1359/JBMR. 050111
53. Wang HJ, Tannukit S, Wen X, Shapiro JL, Snead ML, Paine ML. Using the yeast two-hybrid assay to discover protein partners for the leucine-rich amelogenin peptide and for tuftelin-interacting protein11. Eur J Oral Sci. (2006) 114:276–9. doi: 10.1111/j.1600-0722.2006. 00289.x
54. Zhang H, Tompkins K, Garrigues J, Snead ML, Gibson CW, Somerman MJ. Full length amelogenin binds to cell surface LAMP-1 on tooth root/periodontium associated cells. Arch Oral Biol. (2010) 55:417–25. doi: 10.1016/j.archoralbio.2010.03.009
55. Zou Y, Wang H, Shapiro JL, Okamoto CT, Brookes SJ, Lyngstadaas SP, et al. Determination of protein regions responsible for interactions of amelogenin with CD63 and LAMP1. Biochem J. (2007) 408:347–54. doi: 10.1042/BJ20070881
56. Martins L, Leme AF, Kantovitz KR, de Luciane Martins EN, Sallum EA, Casati MZ, et al. Leucine-Rich Amelogenin Peptide (LRAP) uptake by cementoblast requires flotillin-1 mediated endocytosis. J Cell Physiol. (2017) 232:556–65. doi: 10.1002/jcp.25453
57. Toyoda K, Fukuda T, Sanui T, Tanaka U, Yamamichi K, Atomura R, et al. Grp78 is critical for amelogenin-induced cell migration in a multipotent clonal human periodontal ligament cell line. J Cell Physiol. (2016) 231:414–27. doi: 10.1002/jcp.25087
58. Yang M, Zhang F, Qin K, Wu M, Li H, Zhu H, et al. Glucose- regulated protein 78-induced myeloid antigen presenting cells maintained tolerogenic signature upon LPS stimulation. Front immunol. (2016) 7:552. doi: 10.3389/fimmu.2016.00552
59. Hatakeyama J, Philp D, Hatakeyama Y, Haruyama N, Shum L, Aragon MA, et al. Amelogenin-mediated regulation of osteoclastogenesis, and periodontal cell proliferation and migration. J Dent Res. (2006) 85:144–9. doi: 10.1177/154405910608500206
60. Ravindranath RM, Devarajan A, Bringas P Jr. Enamel formation in vitro in mouse molar explants exposed to amelogenin polypeptides ATMP and LRAP on enamel development. Arch Oral Biol. (2007) 52:1161–71. doi: 10.1016/j.archoralbio.2007.06.008
61. Romanelli M, Dini V, Vowden P, Agren MS. Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to- heal wounds: experimental and clinical evidence. Clin Interv Aging. (2008) 3:263–72. doi: 10.2147/CIA.S1846